Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

ENETS Abstract Search

#4559 Exploring the interplay between RNA methylation and splicing dysregulation in neuroendocrine tumours

Introduction: Post-transcriptional modifications play crucial roles in regulating gene expression and cellular function. While recent findings indicate that alternative splicing dysregulation plays a key role in tumorigenic properties of neuroendocrine tumours (NETs), the role of other RNA processing mechanisms, such as N6-methyladenosine (m6A) — being the most common RNA methylation — remains largely unexplored in NETs.

Conference:

Presenting Author:

Authors: Ruiz-Palacios D, Gutiérrez Camacho L, García Vioque V, Moreno Montilla M, Blázquez-Encinas R,

Keywords: RNA methylation, splicing, neuroendocrine tumour, lung NET, pan NET,

#4531 The role of metabolism in neuroendocrine tumour cell models and patients

Introduction: It is recognised that the adipose tissue plays a major role in cancer through a metabolic coupling that supports tumour cell growth. Recent evidence suggests that altered metabolic pathways drive the development and influence the clinical outcomes of gastroenteropancreatic neuroendocrine tumours (GEP-NETs).

Conference:

Presenting Author: Calabrese C

Authors: Calabrese C, Dellavalle S, Miserocchi G, Gabellone S, Spadazzi C,

Keywords: tumour metabolism, adipocytes, RNA-sequencing, GEP-NET,

#4428 Tumour-derived apolipoprotein E drives temozolomide chemoresistance by reprogramming lipid metabolism and activating the homologous recombination repair pathway in pancreatic neuroendocrine tumours

Introduction: Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumours (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: Temozolomide, pancreatic neuroendocrine tumour, chemoresistance,

#4100 Pheochromocytoma and paraganglioma: Gender differences in lipid profile

Introduction: Pheochromocytoma and paraganglioma (PPGL) are rare neuroendocrine neoplasms potentially influencing lipid metabolism and increasing cardiovascular risk. Gender differences in PPGL are largely unknown.

Conference:

Presenting Author: Di Iasi G

Authors: Di Iasi G, Benevento E, Cannavale G, Liccardi A, Minotta R,

Keywords: gender, Pheochromocytoma, paraganglioma, lipid, cholesterol,

#4098 A case of functional pancreatic neuroendocrine tumor with hypercalcemia as the main manifestation

Introduction: NEN is a type of rare neoplasm originated from peptidenergic neurons and neuroendocrine cells. Even for functional neuroendocrine tumors, the hormones secreted can be temporally and spatially heterogeneous. Hypercalcemia being a rare clinical manifestation of F-pNEN.

Conference:

Presenting Author: Yingmei T

Authors: Yanping Z, Yingmei T, Jieting D,

Keywords: pancreatic neuroendocrine tumor, functional, parathyroid hormone related peptide,